This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...

Diabetic retinopathy remains a major cause of vision loss among working-age individuals worldwide. While chronic hyperglycemia is a well-known risk factor, the study sheds light on the role of acute ...

The Sultanate of Oman is the third country worldwide to implement this project, confirming its commitment to technological ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

Diabetic retinopathy happens when elevated blood sugar levels cause damage to the blood vessels in the retina. The retina plays a crucial role in transmitting visual images to the brain.

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.

Diabetic retinopathy and diabetic macular edema (DME) are two of the most common vision conditions related to diabetes. They affect about 1 in 4 people with type 1 and type 2 diabetes.